Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes

NCT01555814 is registered in ClinicalTrials.gov with Birte Glenthoj as lead sponsor.

NCT NCT01555814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01555814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes
Lead sponsor
Birte Glenthoj
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2011
Completion date
October 31, 2016
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia, schizophreniform disorder